Blog

Taipei Medical University (TMU) stands as a distinguished institution for medical education and research in Taiwan. This forward-thinking system aims to amplify inbound trial opportunities and establish a global presence through a platform for exchanging real-time insights, thereby assisting hospitals and research institutions in maintaining their leadership in clinical research through collaborative industry ventures. 

Especially for patients with advanced or aggressive cancers, time is of the essence. Without access to advanced tools or algorithms, patients may find it challenging to locate trials tailored to their unique medical profile. Recognising this, Oncoshot has developed Recommend Tx, a ground-breaking Large Language Model (LLM) AI feature that interprets free-text cancer information to match cancer patients with high-value clinical trials.

Japan presently ranks as the third-largest pharmaceutical market worldwide. This strategic partnership aims to synergise Buzzreach and Oncoshot’s complementary strengths to enhance various aspects of clinical trials, including feasibility assessments, participant screening, and enrolment throughout Japan.

'Singaporean healthtech leader, Oncoshot, has based its Australian headquarters in Melbourne, to leverage the city's world-leading cancer capability and hospital networks, making it the ideal location to support the company’s international growth.'

Susan's story shed light on the urgent need to constantly match clinical and genomic cancer data to the evolving landscape of clinical trials.

While the incidence of cancer in rural India is nearly half of that of urban India, the mortality rates are double due to the lack of adequate healthcare facilities, awareness about cancer and its risk factors, and limited access to cancer screening and treatment services.

Many cancer patients in India remain largely unaware of clinical trials. However, the recent infrastructural advancements in the local private hospitals make India an ideal platform for conducting clinical trials.

Earlier last year, Oncoshot India signed an MOU with the Basavatarakam Indo-American Cancer Hospital (BIACH) in May. The hospital’s objective is to serve the community and is run on a not-for-profit basis. It is a national-level healthcare institution specialising in cancer capabilities in research and education.

Our goal is to positively impact five million cancer patients globally, but we have recognised that we are also building a platform to support the development of tens, ideally hundreds, of drugs in the long term.

The awards celebrate the achievements of businesses and individuals who are leaders in their fields.

As a provider of clinical development services across all clinical trial phases and therapeutic areas, Novotech will leverage the Oncoshot platform to understand matching populations across key clinical trial markets in the APAC region.

Oncoshot has just announced one of its biggest collaborations to date with Icon Cancer Centre in Singapore, alongside Roche. Together the partners plan to facilitate more comprehensive genomic profiling data to increase access to more trial options for cancer patients.

Oncoshot has established a strategic partnership with Novartis to leverage its Project EISE platform which has the potential to enable more patients to access clinical trials in Singapore. EISE (pronounced as ‘easy’), an acronym for ‘Enhanced Clinical Trial Initiation, Screening and Enrolment,’ is a nationwide collaborative effort that connects cancer patients through an integrated, state-of-the-art care system. 

Check out this insightful video interview of our CEO and Co-Founder Huren Sivaraj about our recent partnership with Omico, the Australian Genomic Medicine Centre. Here he discusses the priorities in the Australian clinical trial ecosystem and the current challenges Oncoshot aims to address.

Oncoshot has just entered into a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre. The respective parties were represented at the event yesterday by Dr Huren Sivaraj, CEO and co-founder of Oncoshot, and Prof David Thomas, CEO of Omico and head of Genomic Cancer Medicine at the Garvan Institute.

Oncoshot today announced a pre-series A funding round led by MassMutual Ventures (MMV). Other investors for this stage come from a suite of healthtech veterans that include Milltrust International and health industry angel investors.

Oncoshot has signed a memorandum of understanding with the Singapore Clinical Research Institute (SCRI), the national coordinating body for clinical trials under the newly launched Consortium for Clinical Research and Innovation Singapore (CRIS). The signing event held last Wednesday was witnessed by guest-of-honour Minister for Health Mr Ong Ye Kung.

SINGAPORE, March 22, 2022 /PRNewswire/ – Oncoshot has announced it will be welcoming Dr Bernard Ng, Chief Scientific Officer of Milltrust Ventures, to its advisory board this month. This comes as a first step as the specialist investment organization finances the fast-growing health tech company founded in Singapore.

AstraZeneca will tap into Oncoshot’s data analytic capabilities of InSite Feasibility to introduce more relevant and innovative cancer clinical trials to Singapore.  

Public and private sectors in Singapore are harnessing genomic data through technologies such as Artificial Intelligence to advance the field of precision oncology.